Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while Vanguard Dividend Appreciation Index Fund ETF trades at $239.05 (market cap $132.40B). The key difference: Vanguard Dividend Appreciation Index Fund ETF is far larger — about 10.5× Halozyme Therapeutics Inc. Common Stock's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Vanguard Dividend Appreciation Index Fund ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Vanguard Dividend Appreciation Index Fund ETF for 134 Days on average.
| HALO | VIG | |
|---|---|---|
Market Cap | $12.58B | $132.40B |
Volume | 2,179,278 | 1,287,188 |
Sector | Health | — |
52-Week High | $115.22 | $246.61 |
52-Week Low | $61.63 | $210.70 |
Typical Hold Time | 1 Days | 134 Days |
Enterprise Value | $14.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VIG trades at $237.39, up 0.17% with a bullish technical signal from moving averages. The ETF focuses on dividend growth stocks with 10+ years of consecutive dividend increases, offering a lower yield but stronger growth profile compared to peers. Recent quarterly dividend increased 7.5% year-to-date, though growth remains below historical averages. Technical indicators show support at $235-236 and resistance at $238-240.
Outlook remains positive for long-term investors seeking dividend growth, though the strategy sacrifices current yield for quality. Risks include slower dividend growth rates and exclusion of high-yield stocks by design. The ETF's quality focus provides defensive characteristics but may underperform during high-yield market environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
